[EHA2014]肿瘤瞭望专访Jean Bernard 终身成就奖得主F Stevenson教授谈B细胞淋巴瘤的免疫疫苗的现状
《肿瘤瞭望》：尊敬的Stevenson教授您好，感谢您接受肿瘤瞭望的采访。我代表中国同仁祝贺您取得了这一奖项。您能与我们分享您的研究成果吗？
Stevenson教授：好的，感谢您的祝福。我主要的成就是研究慢性淋巴细胞白血病的影响预后因素。慢性淋巴细胞白血病分为2种亚型，有不同的预后价值。
在疾病的不同阶段，我们发现不同的免疫球蛋白的改变。在CLL细胞表面的免疫球蛋白有2种不同的亚基。如果一个病人，他的这些可变区基因未突变，病人的预后要比变异的差，所以我们可以监测这些预测疾病的指标。这些预后差的患者可以采用即将上市的新药物予以治疗。其他方面研究显示我所做的是制备抗肿瘤的疫苗及使用基因为基础的疫苗，基因疫苗即将肿瘤抗原序列我疫苗载体。这些现在已被应用于实体肿瘤的临床实验种，我们有2个地方正在开展这项研究。
《肿瘤瞭望》：那您的研究工作下一步计划是什么呢？
Stevenson教授：下一步是进一步观察研究慢性淋巴细胞白血病的2个亚群如何使疾病的有不同的进展，我们看细胞内的信号通路，由B细胞受体参与抗原激活的途径。我们都希望得到分子特征，这可能会导致研发更多的抑制剂。使其能很好的与这些不同公司开发的抑制剂结合。
Oncology Frontier : Professor Stevenson， thank you for being here with Oncology Frontier. On behalf of our Chinese colleagues， I would like to say congratulations on winning your award. Could you please summarize your major achievements for us?
《肿瘤瞭望》：尊敬的Stevenson教授您好，感谢您接受肿瘤瞭望的采访。我代表中国同仁祝贺您取得了这一奖项。您能与我们分享您的研究成果吗？
Professor Stevenson : Yes thank you for the congratulations. My major achievement has been to look at prognostic factors in chronic lymphocytic leukemia. Chronic lymphocytic leukemia can now be divided into 2 subsets with very different prognostic values. The course of the disease is different and what we found was that there are genetic differences in the immunoglobulin molecules. The surface immunoglobulin on CLL cells is different in the 2 subsets of the disease. In one case if they are unmutated， these variable region genes， the patients do much worse than if they are mutated， so we now have something we can look at at the presentation of this disease which will predict the course of the disease. Those patients with a bad prognosis can perhaps be treated earlier with some of the new drugs that are coming in. The other area of research that I have done is to look at preparing vaccines against tumors and we are using genetic based vaccines， gene based vaccines where you put the sequence of the tumor antigen into a vaccine vector. These are being used actually for solid tumors at the moment and they are in clinical trial. Those are the two areas where I have been active.
Stevenson教授：好的，感谢您的祝福。我主要的成就是研究慢性淋巴细胞白血病的影响预后因素。慢性淋巴细胞白血病分为2种亚型，有不同的预后价值。
在疾病的不同阶段，我们发现不同的免疫球蛋白的改变。在CLL细胞表面的免疫球蛋白有2种不同的亚基。如果一个病人，他的这些可变区基因未突变，病人的预后要比变异的差，所以我们可以监测这些预测疾病的指标。这些预后差的患者可以采用即将上市的新药物予以治疗。其他方面研究显示我所做的是制备抗肿瘤的疫苗及使用基因为基础的疫苗，基因疫苗即将肿瘤抗原序列我疫苗载体。这些现在已被应用于实体肿瘤的临床实验种，我们有2个地方正在开展这项研究。
Oncology Frontier : What is your next step in your research work?
《肿瘤瞭望》：那您的研究工作下一步计划是什么呢？
Professor Stevenson : The next step is to look further into chronic lymphocytic leukemia and see why the disease progression is so different in these 2 subsets and for that we are looking at the intracellular pathways， the pathways which are activated by engagement of the B cell receptor by antigens. We are hoping to get molecular signature， which will perhaps lead to more inhibitors being developed. It fits very nicely with a number of inhibitors， which are being developed by various companies.
Stevenson教授：下一步是进一步观察研究慢性淋巴细胞白血病的2个亚群如何使疾病的有不同的进展，我们看细胞内的信号通路，由B细胞受体参与抗原激活的途径。我们都希望得到分子特征，这可能会导致研发更多的抑制剂。使其能很好的与这些不同公司开发的抑制剂结合。
（来源：《肿瘤瞭望》编辑部）